Literature DB >> 21124078

Increased insulin-like growth factor 1 receptor protein expression and gene copy number in small cell lung cancer.

Andrzej Badzio1, Murry W Wynes, Rafal Dziadziuszko, Daniel T Merrick, Marta Pardo, Witold Rzyman, Anna Kowalczyk, Shalini Singh, James Ranger-Moore, Guadalupe Manriquez, Fabien Gaire, Jacek Jassem, Fred R Hirsch.   

Abstract

PURPOSE: Identification of new therapies in small cell lung cancer (SCLC) is urgently needed. Insulin-like growth factor 1 receptor (IGF1R) is a tyrosine kinase receptor implicated in the pathogenesis of several malignancies and is potentially an attractive target for anticancer treatment. Knowledge about IGF1R protein expression, gene copy number, and the prognostic relevance of these features in SCLC is limited.
METHODS: We analyzed IGF1R protein expression and gene copy number in primary tumors from 90 patients with SCLC (67 men and 23 women) who underwent pulmonary resection. IGF1R expression assessed by immunohistochemistry with H scores from 0 to 400 was evaluable in 84 patients and IGF1R gene copy number assessed by silver in situ hybridization technique in 81 patients.
RESULTS: Median H score for IGF1R protein expression was 88 (range, 0-400), and the proportion of positive immunostaining using cutoff H score of 10 was 74%. Increased IGF1R gene copy number (an average of four or more copies per cell) was found in 15 cases (18.5%), five of whom (6.2%) showed gene amplification. There was a significant correlation between protein expression and gene copy number (r = 0.49, p < 0.005). IGF1R expression and gene copy number did not associate with clinicopathological factors such as patient age, tumor size, lymph node involvement, stage, and survival.
CONCLUSIONS: SCLC is characterized by frequent high-IGF1R protein expression, increased gene copy number, and occasional occurrence of true gene amplification. These features may have important implications for future anti-IGF1R therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21124078      PMCID: PMC3356161          DOI: 10.1097/JTO.0b013e3181f38f57

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  25 in total

Review 1.  Inhibition of the IGF-I receptor for treatment of cancer. Kinase inhibitors and monoclonal antibodies as alternative approaches.

Authors:  Yan Wang; Qun-Sheng Ji; Mark Mulvihill; Jonathan A Pachter
Journal:  Recent Results Cancer Res       Date:  2007

2.  Regulation of survivin expression by IGF-1/mTOR signaling.

Authors:  V Vaira; C W Lee; H L Goel; S Bosari; L R Languino; D C Altieri
Journal:  Oncogene       Date:  2006-10-30       Impact factor: 9.867

3.  Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.

Authors:  Anthony W Tolcher; John Sarantopoulos; Amita Patnaik; Kyriakos Papadopoulos; Chia-Chi Lin; Jordi Rodon; Barbara Murphy; Bruce Roth; Ian McCaffery; Kevin S Gorski; Brianne Kaiser; Min Zhu; Hongjie Deng; Greg Friberg; Igor Puzanov
Journal:  J Clin Oncol       Date:  2009-09-28       Impact factor: 44.544

4.  Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.

Authors:  Daniel D Karp; Luis G Paz-Ares; Silvia Novello; Paul Haluska; Linda Garland; Felipe Cardenal; L Johnetta Blakely; Peter D Eisenberg; Corey J Langer; George Blumenschein; Faye M Johnson; Stephanie Green; Antonio Gualberto
Journal:  J Clin Oncol       Date:  2009-04-20       Impact factor: 44.544

5.  Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.

Authors:  Juddi Yeh; Julie Litz; Paula Hauck; Dale L Ludwig; Geoffrey W Krystal
Journal:  Lung Cancer       Date:  2007-11-14       Impact factor: 5.705

Review 6.  The rationale and development of therapeutic insulin-like growth factor axis inhibition for lung and other cancers.

Authors:  D Ross Camidge; Rafal Dziadziuszko; Fred R Hirsch
Journal:  Clin Lung Cancer       Date:  2009-07       Impact factor: 4.785

7.  Prognostic role of insulin-like growth factor receptor-1 expression in small cell lung cancer.

Authors:  Myung Hee Chang; Jeeyun Lee; Joungho Han; Yeon Hee Park; Jin Seok Ahn; Keunchil Park; Myung-Ju Ahn
Journal:  APMIS       Date:  2009-12       Impact factor: 3.205

8.  Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors.

Authors:  Paul Haluska; Heather M Shaw; Gretchen N Batzel; Donghua Yin; Julian R Molina; L Rhoda Molife; Timothy A Yap; M Luisa Roberts; Amarnath Sharma; Antonio Gualberto; Alex A Adjei; Johann S de Bono
Journal:  Clin Cancer Res       Date:  2007-10-01       Impact factor: 12.531

9.  High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients.

Authors:  V Ludovini; G Bellezza; L Pistola; F Bianconi; L Di Carlo; A Sidoni; A Semeraro; R Del Sordo; F R Tofanetti; M G Mameli; G Daddi; A Cavaliere; M Tonato; L Crinò
Journal:  Ann Oncol       Date:  2009-01-19       Impact factor: 32.976

10.  High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507).

Authors:  Yixuan Gong; Evelyn Yao; Ronglai Shen; Aviva Goel; Maria Arcila; Julie Teruya-Feldstein; Maureen F Zakowski; Stanley Frankel; Martin Peifer; Roman K Thomas; Marc Ladanyi; William Pao
Journal:  PLoS One       Date:  2009-10-06       Impact factor: 3.240

View more
  21 in total

Review 1.  Targeting IGF1R pathway in cancer with microRNAs: How close are we?

Authors:  Arathy S Kumar; Suresh K Rayala; Ganesh Venkatraman
Journal:  RNA Biol       Date:  2018-02-01       Impact factor: 4.652

2.  PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer.

Authors:  Hui Yu; Cory Batenchuk; Andrzej Badzio; Theresa A Boyle; Piotr Czapiewski; Daniel C Chan; Xian Lu; Dexiang Gao; Kim Ellison; Ashley A Kowalewski; Christopher J Rivard; Rafal Dziadziuszko; Caicun Zhou; Maen Hussein; Donald Richards; Sharon Wilks; Marc Monte; William Edenfield; Jerome Goldschmidt; Ray Page; Brian Ulrich; David Waterhouse; Sandra Close; Jacek Jassem; Kimary Kulig; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2016-09-14       Impact factor: 15.609

3.  Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression.

Authors:  Eric Polley; Mark Kunkel; David Evans; Thomas Silvers; Rene Delosh; Julie Laudeman; Chad Ogle; Russell Reinhart; Michael Selby; John Connelly; Erik Harris; Nicole Fer; Dmitriy Sonkin; Gurmeet Kaur; Anne Monks; Shakun Malik; Joel Morris; Beverly A Teicher
Journal:  J Natl Cancer Inst       Date:  2016-05-31       Impact factor: 13.506

Review 4.  Targeted drugs in small-cell lung cancer.

Authors:  Mariacarmela Santarpia; Maria Grazia Daffinà; Niki Karachaliou; Maria González-Cao; Chiara Lazzari; Giuseppe Altavilla; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2016-02

Review 5.  Insulin-like growth factor receptor 1 (IGF1R) expression and survival in non-small cell lung cancer patients: a meta-analysis.

Authors:  Shuang Zhao; Zhixin Qiu; Jinlan He; Lei Li; Weimin Li
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

6.  Thymidylate synthase protein expression by IHC and gene copy number by SISH correlate and show great variability in non-small cell lung cancer.

Authors:  Murry W Wynes; Krzysztof Konopa; Shalini Singh; Bernadette Reyna-Asuncion; James Ranger-Moore; Adam Sternau; Daniel C Christoph; Rafal Dziadziuszko; Jacek Jassem; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2012-06       Impact factor: 15.609

7.  Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer.

Authors:  Rafal Dziadziuszko; Murry W Wynes; Shalini Singh; Bernadette Reyna Asuncion; James Ranger-Moore; Krzysztof Konopa; Witold Rzyman; Barbara Szostakiewicz; Jacek Jassem; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2012-02       Impact factor: 15.609

Review 8.  The insulin and insulin-like growth factor receptor family in neoplasia: an update.

Authors:  Michael Pollak
Journal:  Nat Rev Cancer       Date:  2012-02-16       Impact factor: 60.716

9.  FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.

Authors:  Murry W Wynes; Trista K Hinz; Dexiang Gao; Michael Martini; Lindsay A Marek; Kathryn E Ware; Michael G Edwards; Diana Böhm; Sven Perner; Barbara A Helfrich; Rafal Dziadziuszko; Jacek Jassem; Szymon Wojtylak; Aleksandra Sejda; Joseph M Gozgit; Paul A Bunn; D Ross Camidge; Aik-Choon Tan; Fred R Hirsch; Lynn E Heasley
Journal:  Clin Cancer Res       Date:  2014-04-25       Impact factor: 12.531

Review 10.  Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors.

Authors:  Rita Dorantes-Heredia; José Manuel Ruiz-Morales; Fernando Cano-García
Journal:  Transl Lung Cancer Res       Date:  2016-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.